Equities analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will announce earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.37). Iovance Biotherapeutics posted earnings of ($0.26) per share in the same quarter last year, which would indicate a negative year over year growth rate of 11.5%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.23) per share for the current year, with EPS estimates ranging from ($1.47) to ($0.72). For the next year, analysts expect that the business will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.69) to ($0.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Iovance Biotherapeutics.
Several brokerages recently weighed in on IOVA. Chardan Capital reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Wednesday, March 13th. Oppenheimer reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, March 19th. Robert W. Baird began coverage on Iovance Biotherapeutics in a report on Wednesday, February 6th. They issued an “outperform” rating and a $29.00 price objective for the company. BidaskClub raised Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, ValuEngine lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.86.
Hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. boosted its stake in Iovance Biotherapeutics by 58.6% in the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 3,000 shares during the period. Kalos Management Inc. bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $93,000. Great West Life Assurance Co. Can boosted its position in shares of Iovance Biotherapeutics by 67.4% during the 4th quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 5,853 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $130,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Iovance Biotherapeutics by 66.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,374 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 6,162 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Further Reading: Do closed-end mutual funds pay dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.